Related Experiment Video
Updated: May 9, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Low fetuin-A level in migraine: a case-control study
Mehmet Halis Tanriverdi1, Sefer Varol, Adalet Arikanoglu
1Department of Family Medicine, Faculty of Medicine, School of Medicine, Dicle University, 21280, Diyarbakir, Turkey, dr.mht@hotmail.com.
Abstract:
Migraine is a type of primary headache which is caused by the alterations in trigeminovascular system. Migraine attacks are associated with neurovascular inflammation of the cerebral and extracerebral vessels, but its pathophysiological mechanisms have not still been fully delineated. Also, migraine has been found to be associated with higher risks for various metabolic disorders. Thus, we aimed to investigate the matrix metalloproteinases (MMP), fetuin-A, ghrelin, and omentin levels which have important roles in metabolic disorders and inflammation, and to examine their relationship with migraine subtypes and attack frequency. Forty-nine migraine patients and 30 age- and sex-matched healthy control subjects were enrolled. Migraine diagnosis was confirmed according to the International Classification of Headache Disorders-II diagnostic criteria. Analyses of MMP9,MMP3, ghrelin, omentin, and fetuin-A were performed by the ELISA method. Fetuin-A, MMP-9, and MMP-3 levels were significantly lower in migraine than controls (p < 0.05). There were no significant differences between groups with respect to omentin and ghrelin (p > 0.05). In migraine patients, serum fetuin-A levels were positively correlated with MMP-9 and negatively correlated with MMP-3. MMP-3, MMP-9, fetuin-A, omentin and ghrelin levels did not correlate with age, disease duration, or frequency of migraine headache (p > 0.05). Migraine patients have lower fetuin-A, MMP-3 and MMP-9 levels than healthy individuals. Migraine patients have low fetuin-A levels, which may be related to the pathogenesis of migraine. The importance and impact of our findings on the pathogenesis, characteristics, and treatment of migraine needs to be investigated in further detailed studies.
Insights
Migraine patients show lower levels of fetuin-A, matrix metalloproteinase-3 (MMP-3), and MMP-9 compared to healthy individuals. Low fetuin-A may play a role in migraine pathogenesis.
Area of Science:
- Neurology
- Biochemistry
- Metabolic Disorders
Background:
- Migraine pathogenesis involves trigeminovascular system alterations and neurovascular inflammation.
- Migraine is linked to an increased risk of metabolic disorders.
- Specific biomarkers like matrix metalloproteinases (MMP), fetuin-A, ghrelin, and omentin are implicated in metabolic and inflammatory processes.
Purpose of the Study:
- To investigate serum levels of MMPs, fetuin-A, ghrelin, and omentin in migraine patients.
- To examine the relationship between these biomarkers and migraine subtypes or attack frequency.
Main Methods:
- Enrolled 49 migraine patients and 30 healthy controls, diagnosed using the International Classification of Headache Disorders-II criteria.
- Measured serum levels of MMP-9, MMP-3, ghrelin, omentin, and fetuin-A using ELISA.
- Analyzed correlations between biomarker levels and clinical parameters like age, disease duration, and attack frequency.
Main Results:
- Migraine patients exhibited significantly lower serum levels of fetuin-A, MMP-9, and MMP-3 compared to controls (p < 0.05).
- No significant differences were observed in omentin and ghrelin levels between groups (p > 0.05).
- In migraine patients, serum fetuin-A positively correlated with MMP-9 and negatively with MMP-3; no biomarkers correlated with age, disease duration, or attack frequency.
Conclusions:
- Migraine patients demonstrate reduced levels of fetuin-A, MMP-3, and MMP-9.
- Lower fetuin-A levels in migraine patients may contribute to the condition's pathogenesis.
- Further research is needed to elucidate the impact of these findings on migraine's pathogenesis, characteristics, and treatment.
